MarketWatch In the study, presented by Katja Weisel, M.D., Department of Medicine, University Hospital Tubingen, Tubingen, Germany, 455 patients were randomized to receive either pomalidomide plus low-dose dexamethasone (n=302) or high-dose dexamethasone ... and more »
DailyFinance SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NAS: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved the company's sup...
Labmate Online TOURMALINE-MM1 is investigating MLN9708 in combination with lenalidomide and dexamethasone in relapsed and/or refractory MM, while TOURMALINE-MM2 is looking at MLN9708 when mixed with lenalidomide and dexamethasone in patients with ...
iStockAnalyst (press release) Hepatic failure, including fatal cases, has occurred in patients treated with Revlimid in combination with dexamethasone . "The approval o...
NASDAQ Celgene also presented encouraging updated data from an international late-stage study (MM-003) which evaluated Pomalyst combined with low-dose dexamethasone versus high-dose dexamethasone in previously treated MM patients. Data from a study ... and more »
National Post Serious tumor flare reactions have occurred during investigational use of REVLIMID for chronic lymphocytic leukemia and lymphoma. Hepatic failure, including fatal cases, has occurred in patients treated with REVLIMID in combination with dexamethasone .
